ATE405254T1 - Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase - Google Patents

Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase

Info

Publication number
ATE405254T1
ATE405254T1 AT99946522T AT99946522T ATE405254T1 AT E405254 T1 ATE405254 T1 AT E405254T1 AT 99946522 T AT99946522 T AT 99946522T AT 99946522 T AT99946522 T AT 99946522T AT E405254 T1 ATE405254 T1 AT E405254T1
Authority
AT
Austria
Prior art keywords
tolterodine
antimuscarino
act
treatment
hyperactive bladder
Prior art date
Application number
AT99946522T
Other languages
English (en)
Inventor
Jacobsen Lene Orup
Rd Bo Kreilg
Ulla Hoeck
Helle Kristensen
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE405254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE405254T1 publication Critical patent/ATE405254T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99946522T 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase ATE405254T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
ATE405254T1 true ATE405254T1 (de) 2008-09-15

Family

ID=20412370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946522T ATE405254T1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase

Country Status (13)

Country Link
US (2) US6517864B1 (de)
EP (1) EP1105111B1 (de)
JP (1) JP2002523446A (de)
AT (1) ATE405254T1 (de)
AU (1) AU758399B2 (de)
CA (1) CA2341063C (de)
DE (1) DE69939382D1 (de)
ES (2) ES2353765T3 (de)
NZ (1) NZ509928A (de)
SE (1) SE9802864D0 (de)
TW (1) TWI253349B (de)
WO (1) WO2000012070A1 (de)
ZA (1) ZA200002488B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
WO2003053292A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040191345A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2005011683A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
KR20130069764A (ko) * 2005-02-03 2013-06-26 교린 세이야꾸 가부시키 가이샤 경피 흡수형 제제
US10010494B2 (en) 2005-10-19 2018-07-03 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
CN101472644B (zh) * 2006-04-13 2014-04-23 纽帕特公司 递送抗偏头痛化合物的透皮方法和系统
AU2012261753B2 (en) * 2006-04-13 2015-03-05 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
RU2492175C2 (ru) 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
EP2307546A1 (de) * 2008-06-04 2011-04-13 Coda Therapeutics, Inc. Schmerzbehandlung mit gap-junction-modulationsverbindungen
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
ME02702B (de) 2008-08-22 2017-10-20 Theracos Sub Llc Verfahren zur herstellung von sglt2-hemmern
EP2379561B1 (de) 2008-11-25 2015-11-04 University Of Rochester Mlk-inhibitoren und anwendungsverfahren
US8697661B2 (en) 2009-06-24 2014-04-15 Christine Kritikou Use of spinosyns and spinosyn compositions against herpesviridae viral infections
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
CN105748401A (zh) * 2009-08-10 2016-07-13 泰华制药国际有限公司 用离子电渗疗法治疗恶心和偏头痛的方法
WO2011046927A1 (en) * 2009-10-13 2011-04-21 Nupathe,Inc. Transdermal methods and systems for the delivery of rizatriptan
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
KR101746204B1 (ko) 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR20110094858A (ko) * 2010-02-18 2011-08-24 에스케이케미칼주식회사 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물
CN102858372A (zh) * 2010-04-28 2013-01-02 久光制药株式会社 皮肤刺激抑制剂和经皮吸收制剂
WO2011149950A2 (en) 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
JP5642790B2 (ja) * 2010-08-03 2014-12-17 久光製薬株式会社 貼付剤及びその粘着力増強方法
EP2654757A1 (de) 2010-12-22 2013-10-30 Entarco SA Verwendung von spinosynen und spinosynzusammensetzungen als lokalanästhetika und antiarrhythmika
EP2675893B1 (de) 2011-02-18 2019-01-09 The Scripps Research Institute Gezielte differenzierung von oligodendrozyten-vorläuferzellen für ein myelinierungs-zellschicksal
JP6087839B2 (ja) * 2011-12-27 2017-03-01 帝國製薬株式会社 トルテロジン含有貼付剤
WO2013148736A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
NZ701949A (en) 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
JP6153135B2 (ja) 2012-06-12 2017-06-28 株式会社 ケイ・エム トランスダーム 貼付剤
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
CN103142465B (zh) * 2013-03-19 2014-10-22 长春健欣生物医药科技开发有限公司 一种托特罗定成膜水凝胶制剂及其制备方法
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
WO2018184019A1 (en) 2017-03-31 2018-10-04 Curza Global, Llc Compositions and methods comprising substituted 2-aminoimidazoles
MX2021002002A (es) 2018-08-23 2021-05-31 Seagen Inc Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit).
US20230354981A1 (en) * 2020-07-23 2023-11-09 Kimberly-Clark Worldwide, Inc. Method for modulating the bladder microbiome to improve bladder health
KR20230104659A (ko) 2020-11-08 2023-07-10 씨젠 인크. 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체
KR20230165911A (ko) 2021-04-09 2023-12-05 씨젠 인크. 항-tigit 항체를 사용한 암의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ES2137261T3 (es) 1992-05-13 1999-12-16 Alza Corp Administracion transdermica de oxibutinina.
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2232435C (en) * 1996-08-09 2006-11-14 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
ES2310942T3 (es) 2009-01-16
AU5891999A (en) 2000-03-21
JP2002523446A (ja) 2002-07-30
SE9802864D0 (sv) 1998-08-27
EP1105111A1 (de) 2001-06-13
EP1105111B1 (de) 2008-08-20
ES2353765T3 (es) 2011-03-04
DE69939382D1 (de) 2008-10-02
NZ509928A (en) 2003-08-29
TWI253349B (en) 2006-04-21
CA2341063C (en) 2008-02-12
WO2000012070A1 (en) 2000-03-09
US6517864B1 (en) 2003-02-11
AU758399B2 (en) 2003-03-20
CA2341063A1 (en) 2000-03-09
ZA200002488B (en) 2001-05-16
US20030124179A1 (en) 2003-07-03
US7008637B2 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
ATE405254T1 (de) Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EE9700187A (et) Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
ATE362770T1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE602004017481D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
NO20000293L (no) Preparater, kits og fremgangsmõter for inhibering av cerebrale neurovaskulære forstyrrelser og muskulære hodepiner
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
Toda et al. Human uterine arterial relaxation induced by nitroxidergic nerve stimulation
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
SE9804126D0 (sv) New pharmaceutical composition
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
SE0301884D0 (sv) New use III
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
SE0301885D0 (sv) New use IV
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0303610A2 (hu) Jóindulatú prosztatatúltengéssel összefüggő húgyhólyag-irritációs tünetek kezelésére alkalmas készítmény
DE60017793D1 (de) Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties